Mario J. Pineda

Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.

Journal: Cancer research communications

Published: November 17, 2022

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.

Journal: Gynecologic oncology

Published: April 29, 2021

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Journal: Gynecologic oncology

Published: August 30, 2018

Safety and dose modification for patients receiving niraparib.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 15, 2018

A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer.

Journal: Gynecologic oncology research and practice

Published: July 18, 2018

Safety and dose modification for patients receiving niraparib.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 17, 2018

FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.

Journal: Journal of genetic counseling

Published: November 22, 2016

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 03, 2016

Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.

Journal: Hormones & cancer

Published: February 11, 2015

What is integrative oncology and can it help my patients?

Journal: Obstetrics and gynecology clinics of North America

Published: May 30, 2012

Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.

Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Safety and dose modification for patients receiving niraparib.

Safety and dose modification for patients receiving niraparib.

A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer.

A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer.

Safety and dose modification for patients receiving niraparib.

Safety and dose modification for patients receiving niraparib.

FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.

FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.

Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.

What is integrative oncology and can it help my patients?

What is integrative oncology and can it help my patients?

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.